Wegovy is a concentrated form of semaglutide, a GLP-1 receptor drug approved by the FDA to manage type 2 diabetes and weight loss. Wegovy is similar to Ozempic and manufactured by the same drug company, Novo Nordisk. As we’ve reported recently, patients who suffered from gastroparesis and blindness after taking Ozempic are filing cases against the drug’s manufacturer. These cases have been consolidated into a multidistrict litigation. Here are the latest updates about the Wegovy lawsuit:
Wegovy Lawsuit Cases Continue to Increase
There are 1,300 active lawsuits against Wegovy manufacturers included in the MDL as of December 2nd. Earlier this year, MDL cases increased by 20% as more studies were released that connect semaglutide with gastroparesis diagnosis. News coverage sharing stories from plaintiffs has also increased the MDL’s visibility and has prompted more to enter their cases into the MDL.
Using Semaglutide Increases Risk of Gastroparesis
Media coverage of the adverse effects of taking Wegovy and Ozempic is increasing. This Time Magazine article shares the details of several patients who took semaglutide and were later diagnosed with serious gastrointestinal issues. Symptoms the patients experienced include:
- Excessive vomiting
- Deteriorating muscles
- Oral issues related to vomiting and excessive stomach acid
- Gastroparesis
The article cites studies that claim more than 50% of patients taking semaglutide drugs suffer from nausea and vomiting. These studies also link semaglutide use with gastroparesis, stomach inflammation, blood clots, eye stroke, and blindness.
Plaintiffs Move to Include Marketing Campaigns in Discovery
Wegovy and Ozempic drug manufacturers have invested millions into marketing campaigns since the drug was approved by the FDA in 2021. This expanded the popularity of the drug being prescribed. Online influencers were also used to help promote the drug on social media. Plaintiffs in the Wegovy lawsuit MDL claim that the drug’s marketing campaigns significantly influenced their decision to use Wegovy. Plaintiffs’ legal teams have requested that Judge Karen Spencer Marston allow marketing campaigns into early discovery to be included with the case. Continue following us for future updates.
Key Injury Criteria for Wegovy Lawsuit Victims
Our team is currently accepting Wegovy lawsuit cases. If you had at least two injections of Wegovy and were later diagnosed with any of the illnesses below, you may be eligible for compensation:
- Gastroparesis
- Gallbladder disorders
- Ischemic Optic Neuropathy (eye stroke)
- Pancreatitis
- Diabetic Retinopathy
- Intestinal blockage or obstruction
We’re Now Accepting Wegovy Lawsuit Cases
Wegovy’s drug label didn’t warn patients about the potential of gastrointestinal issues with the use of Wegovy until 2022. Patients who were prescribed Wegovy before this date and later diagnosed with gastroparesis or non-arteritic anterior Ischemic Optic Neuropathy (NAION) could be eligible for compensation for the medical expenses. Contact our legal team today at Michael Brady Lynch Firm at 888-585-5970 for a consultation to see whether you’re eligible to join the Weogvy MDL.
For more information about Ozempic and Wegovy lawsuits, check out these posts: